Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
Evommune's lead candidate, EVO756 is a potent and highly selective oral small molecule antagonist of MRGPRX2 for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). It is joined by EV0301, a long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain for the treatment of atopic dermatitis (AD) and ulcerative colitis (UC). Evommune initiated a Phase 2b trail for EVO756 and is expected to report results in 2H26, and plans to initiate a Phase 2 trial in moderate-to-severe UC patients in 2026.
The Palo Alto, CA-based company was founded in 2020 and booked $3 million in revenue for the 12 months ended June 30, 2025. It plans to list on the NYSE under the symbol EVMN. Evommune filed confidentially on May 14, 2025. Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
